1. Home
  2. ARTL vs BIAF Comparison

ARTL vs BIAF Comparison

Compare ARTL & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Artelo Biosciences Inc.

ARTL

Artelo Biosciences Inc.

HOLD

Current Price

$1.40

Market Cap

4.3M

Sector

Health Care

ML Signal

HOLD

Logo bioAffinity Technologies Inc.

BIAF

bioAffinity Technologies Inc.

HOLD

Current Price

$1.66

Market Cap

4.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ARTL
BIAF
Founded
2011
2014
Country
United States
United States
Employees
7
57
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.3M
4.6M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ARTL
BIAF
Price
$1.40
$1.66
Analyst Decision
Hold
Analyst Count
2
0
Target Price
N/A
N/A
AVG Volume (30 Days)
801.0K
191.8K
Earning Date
05-13-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$20.95
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.01
$0.23
52 Week High
$28.60
$13.50

Technical Indicators

Market Signals
Indicator
ARTL
BIAF
Relative Strength Index (RSI) 33.35 36.96
Support Level $1.08 $1.23
Resistance Level $1.50 $1.79
Average True Range (ATR) 0.23 0.16
MACD 0.04 0.01
Stochastic Oscillator 16.20 34.63

Price Performance

Historical Comparison
ARTL
BIAF

About ARTL Artelo Biosciences Inc.

Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.

About BIAF bioAffinity Technologies Inc.

bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.

Share on Social Networks: